Top Abstract Purchase Related
Home
>
Node
>
Subnode

IgG synthesis in the cerebrospinal fluid in patients with the chronic progressive phase of multiple sclerosis treated with cyclophosphamide and ACTH

Wender, M.; Michałowska, G.

Neurologia i Neurochirurgia Polska 20(6): 536-541

1986

ISSN/ISBN: 0028-3843
PMID: 3037408
Document Number: 272875
In 30 cases of multiple sclerosis in the chronic-progressive phase treated with cyclophosphamide (total dose 4000 mg) and ACTH (total dose 1050 units) IgG and albumin were determined in the serum and cerebrospinal fluid by Mancini's method. From these determination the IgG, albumin ratio and the IgG index were calculated as markers of IgG synthesis in CSF spaces. As a result of these investigations it is suggested that the treatment of patients with multiple sclerosis in chronic-progressive phase with short-lasting intensive immunosuppression using cyclophosphamide and ACTH causes no significant changes in IgG synthesis in CSF spaces.

Document emailed within 1 workday
Secure & encrypted payments

Wender, M.; Tokarz-Kupczyk, E.; Mularek, O. 1988: Early results of the treatment of chronic progressive forms of multiple sclerosis with cyclophosphamide and ACTH Neurologia i Neurochirurgia Polska 22(5): 399-403
Carter, J.L.; Hafler, D.A.; Dawson, D.M.; Orav, J.; Weiner, H.L. 1988: Immunosuppression with high-dose I.v. cyclophosphamide and ACTH in progressive multiple sclerosis: cumulative 6-year experience in 164 patients Neurology 38(7 Suppl 2: 9-14
Zamboni, P.; Menegatti, E.; Weinstock-Guttman, B.; Schirda, C.; Cox, J.L.; Malagoni, A.M.; Hojanacki, D.; Kennedy, C.; Carl, E.; Dwyer, M.G.; Bergsland, N.; Galeotti, R.; Hussein, S.; Bartolomei, I.; Salvi, F.; Zivadinov, R. 2009: The severity of chronic cerebrospinal venous insufficiency in patients with multiple sclerosis is related to altered cerebrospinal fluid dynamics Functional Neurology 24(3): 133-138
Watanabe, T.; Yamamoto, T.; Saito, T.; Sugano, M.; Tsukamoto, T. 1993: Pulse-dose cyclophosphamide therapy for chronic progressive multiple sclerosis Rinsho Shinkeigaku 33(1): 15-20
Kaleemullah, A.J.; O'Kell, R.T. 1976: Evaluation of multiple sclerosis patients by cerebrospinal fluid Missouri Medicine 73(9): 520-522
Trouillas, P.; Neuschwander, P.; Nighoghossian, N.; Adeleine, P.; Tremisi, P. 1989: Intensive immunosuppression in progressive multiple sclerosis. An open study comparing 3 groups: cyclophosphamide, cyclophosphamide-plasmapheresis and control subjects. Results after 3 years Revue Neurologique (Paris) 145(5): 369-377
Tsai, S.J.; Chiu, H.C.; Su, C.L.; Wang, C.R. 1990: Cerebrospinal fluid study in Chinese patients with multiple sclerosis Zhonghua Minguo Wei Sheng Wu Ji Mian Yi Xue Za Zhi 23(2): 189-196
Seres, E.; Bencsik, K.; Rajda, C.; Vécsei, L. 1998: Diagnostic studies of cerebrospinal fluid in patients with multiple sclerosis Orvosi Hetilap 139(32): 1905-1908
Duquette, P.; Charest, L. 1986: Cerebrospinal fluid findings in healthy siblings of multiple sclerosis patients Neurology 36(5): 727-729
Neu, I. 1981: Essential fatty acids in serum and cerebrospinal fluid of patients during multiple sclerosis Der Nervenarzt 52(2): 100-107
Lubetzki, C.; Lombrail, P.; Hauw, J.J.; Baumann, N.; Zalc, B. 1987: Binding of immunoglobulins of the cerebrospinal fluid of multiple sclerosis patients to oligodendrocytes in culture Pathologie-Biologie 35(3): 314-318
Zephir, H.; De-Seze, J.; Senechal, O.; Stojkovic, T.; Ferriby, D.; Delisse, B.; Dubus, B.; Verier, A.; Hautecoeur, P.; Vermersch, P. 2002: Treatment of progressive multiple sclerosis with cyclophosphamide Revue Neurologique (Paris) 158(1): 65-69
Tourtellotte, W.W.; Syndulko, K.; Baumhefner, R.W.; Shapshak, P.; Osborne, M. 1988: A comprehensive protocol for clinical trials in multiple sclerosis which favored azathioprine and corticosteroid as a type of treatment for the chronic progressive phase Neurology 38(7 Suppl 2: 83-86
Tavolato, B. 1972: Immunoglobulin G in cerebrospinal fluid of patients with multiple sclerosis. Study with immunosuppression. Preliminary report Acta Neurologica 27(2): 121-122
Rodriguez, M.; Wynn, D.R.; Kimlinger, T.K.; Katzmann, J.A. 1990: Terminal component of complement (C9) in the cerebrospinal fluid of patients with multiple sclerosis and neurologic controls Neurology 40(5): 855-857
Stelmasiak, Z.; Bartosik-Psujek, H.; Belniak-Legieć, E.; Mitosek-Szewczyk, K. 2000: The effect of cladribine on some parameters of blood and cerebrospinal fluid in patients with relapsing-remitting multiple sclerosis (RR-MS) Annales Universitatis Mariae Curie-Sklodowska. Sectio D: Medicina 55: 221-225
Tournier-Lasserve, E.; Lyoncaen, O.; Roullet, E.; Bach, M.A. 1987: IL-2 receptor and HLA class Ii antigens on cerebrospinal fluid cells of patients with multiple sclerosis and other neurological diseases Clinical and Experimental Immunology 67(3): 581-586
Niezgoda, A.; Losy, J. 2000: The effect of cladribine treatment on beta-2 microglobin in the cerebrospinal fluid and serum of patients with multiple sclerosis Neurologia i Neurochirurgia Polska 34(2): 281-287
Massaro, A.R.; De Pascalis, D.; Carnevale, A.; Carbone, G. 2009: The neural cell adhesion molecule (NCAM) present in the cerebrospinal fluid of multiple sclerosis patients is unsialylated European Review for Medical and Pharmacological Sciences 13(5): 397-399
Castro, H.J.; Mendez-Lnocencio, J.I.; Omidvar, B.; Omidvar, J.; Santilli, J.; Nielsen, H.S.; Pavot, A.P.; Richert, J.R.; Bellanti, J.A. 2005: A phase i study of the safety of honeybee venom extract as a possible treatment for patients with progressive forms of multiple sclerosis Allergy and Asthma Proceedings 26(6): 470-476